I 
119TH CONGRESS 
1ST SESSION H. R. 1266 
To prohibit certain uses of xylazine, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
FEBRUARY 12, 2025 
Mr. PANETTA (for himself, Mr. PFLUGER, Mr. BILIRAKIS, Mr. PAPPAS, Mr. 
FITZGERALD, Ms. ROSS, Mr. CRENSHAW, Mr. HARDER of California, Ms. 
DELBENE, Mrs. MILLER-MEEKS, Ms. PETTERSEN, Ms. CLARKE of New 
York, Mr. DELUZIO, Mr. MAGAZINER, Mr. BACON, Mr. OBERNOLTE, Mr. 
COSTA, Mr. BALDERSON, Ms. BARRAGA´N, Mr. CISCOMANI, Mr. CAREY, 
Mrs. BICE, Ms. CRAIG, Mr. NORCROSS, Mr. FONG, Ms. TENNEY, Mr. 
FITZPATRICK, Mr. BURCHETT, Ms. DEAN of Pennsylvania, Mr. COHEN, 
Mr. DAVIS of North Carolina, Mr. CORREA, Mr. WEBSTER of Florida, 
Mr. COLLINS, Mr. SUOZZI, and Mrs. HARSHBARGER) introduced the fol-
lowing bill; which was referred to the Committee on Energy and Com-
merce, and in addition to the Committee on the Judiciary, for a period 
to be subsequently determined by the Speaker, in each case for consider-
ation of such provisions as fall within the jurisdiction of the committee 
concerned 
A BILL 
To prohibit certain uses of xylazine, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This title may be cited as the ‘‘Combating Illicit 
Xylazine Act’’. 
VerDate Sep 11 2014 
22:27 Mar 10, 2025
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H1266.IH
H1266
kjohnson on DSK7ZCZBW3PROD with $$_JOB
SEC. 2. DEFINITIONS. 
(a) IN GENERAL.—In this title, the term ‘‘xylazine’’ 
has the meaning given the term in paragraph (60) of sec-
tion 102 of the Controlled Substances Act, as added by 
subsection (b) of this section. 
(b) CONTROLLED SUBSTANCES ACT.—Section 102 of 
the Controlled Substances Act (21 U.S.C. 802) is amend-
ed by adding at the end the following: 
‘‘(60) The term ‘xylazine’ means the substance 
xylazine, including its salts, isomers, and salts of isomers 
whenever the existence of such salts, isomers, and salts 
of isomers is possible.’’. 
SEC. 3. ADDING XYLAZINE TO SCHEDULE III. 
Schedule III of section 202(c) of the Controlled Sub-
stances Act (21 U.S.C. 812) is amended by adding at the 
end the following: 
‘‘(f) Unless specifically excepted or unless listed in 
another schedule, any material, compound, mixture, or 
preparation which contains any quantity of xylazine.’’. 
SEC. 4. AMENDMENTS. 
(a) AMENDMENT.—Section 102 of the Controlled 
Substances Act (21 U.S.C. 802) is amended by striking 
paragraph (27) and inserting the following: 
‘‘(27)(A) Except as provided in subparagraph (B), 
the term ‘ultimate user’ means a person who has lawfully 
obtained, and who possesses, a controlled substance for 
VerDate Sep 11 2014 
22:27 Mar 10, 2025
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H1266.IH
H1266
kjohnson on DSK7ZCZBW3PROD with $$_JOB
the use by the person or for the use of a member of the 
household of the person or for an animal owned by the 
person or by a member of the household of the person. 
‘‘(B)(i) In the case of xylazine, other than for a drug 
product approved under subsection (b) or (j) of section 
505 of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 355), the term ‘ultimate user’ means a person— 
‘‘(I) to whom xylazine was dispensed by— 
‘‘(aa) a veterinarian registered under this 
Act; or 
‘‘(bb) a pharmacy registered under this 
Act pursuant to a prescription of a veterinarian 
registered under this Act; and 
‘‘(II) who possesses xylazine for— 
‘‘(aa) an animal owned by the person or by 
a member of the household of the person; 
‘‘(bb) an animal under the care of the per-
son; 
‘‘(cc) use in government animal-control 
programs authorized under applicable Federal, 
State, Tribal, or local law; or 
‘‘(dd) use in wildlife programs authorized 
under applicable Federal, State, Tribal, or local 
law. 
VerDate Sep 11 2014 
22:27 Mar 10, 2025
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H1266.IH
H1266
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(ii) In this subparagraph, the term ‘person’ in-
cludes— 
‘‘(I) a government agency or business where 
animals are located; and 
‘‘(II) an employee or agent of an agency or 
business acting within the scope of their employment 
or agency.’’. 
(b) FACILITIES.—An entity that manufactures 
xylazine, as of the date of enactment of this Act, shall 
not be required to make capital expenditures necessary to 
install the security standard required of schedule III of 
the Controlled Substances Act (21 U.S.C. 801 et seq.) for 
the purposes of manufacturing xylazine. 
(c) LABELING.—The requirements related to label-
ing, packaging, and distribution logistics of a controlled 
substance in schedule III of section 202(c) of the Con-
trolled Substances Act (21 U.S.C. 812(c)) shall not take 
effect for xylazine until the date that is 1 year after the 
date of enactment of this Act. 
(d) PRACTITIONER REGISTRATION.—The require-
ments related to practitioner registration, inventory, and 
recordkeeping of a controlled substance in schedule III of 
section 202(c) of the Controlled Substances Act (21 
U.S.C. 812(c)) shall not take effect for xylazine until the 
date that is 60 days after the date of enactment of this 
VerDate Sep 11 2014 
22:27 Mar 10, 2025
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H1266.IH
H1266
kjohnson on DSK7ZCZBW3PROD with $$_JOB
Act. A practitioner that has applied for registration during 
the 60-day period beginning on the date of enactment of 
this Act may continue their lawful activities until such ap-
plication is approved or denied. 
(e) MANUFACTURER TRANSITION.—The Food and 
Drug Administration and the Drug Enforcement Adminis-
tration shall facilitate and expedite the relevant manufac-
turer submissions or applications required by the place-
ment of xylazine on schedule III of section 202(c) of the 
Controlled Substances Act (21 U.S.C. 812(c)). 
(f) CLARIFICATION.—Nothing in this title, or the 
amendments made by this title, shall be construed to re-
quire the registration of an ultimate user of xylazine under 
the Controlled Substances Act (21 U.S.C. 801 et seq.) in 
order to possess xylazine in accordance with subparagraph 
(B) of section 102(27) of that Act (21 U.S.C. 802(27)), 
as added by subsection (a) of this section. 
SEC. 5. ARCOS TRACKING. 
Section 307(i) of the Controlled Substances Act (21 
U.S.C. 827(i)) is amended— 
(1) in the matter preceding paragraph (1)— 
(A) by inserting ‘‘or xylazine’’ after 
‘‘gamma hydroxybutyric acid’’; 
(B) by inserting ‘‘or 512’’ after ‘‘section 
505’’; and 
VerDate Sep 11 2014 
22:27 Mar 10, 2025
Jkt 059200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H1266.IH
H1266
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(C) by inserting ‘‘respectively,’’ after ‘‘the 
Federal Food, Drug, and Cosmetic Act,’’; and 
(2) in paragraph (6), by inserting ‘‘or xylazine’’ 
after ‘‘gamma hydroxybutyric acid’’. 
SEC. 6. SENTENCING COMMISSION. 
Pursuant to its authority under section 994(p) of title 
28, United States Code, the United States Sentencing 
Commission shall review and, if appropriate, amend its 
sentencing guidelines, policy statements, and official com-
mentary applicable to persons convicted of an offense 
under section 401 of the Controlled Substances Act (21 
U.S.C. 841) or section 1010 of the Controlled Substances 
Import and Export Act (21 U.S.C. 960) to provide appro-
priate penalties for offenses involving xylazine that are 
consistent with the amendments made by this title. In car-
rying out this section, the Commission should consider the 
common forms of xylazine as well as its use alongside 
other scheduled substances. 
SEC. 7. REPORT TO CONGRESS ON XYLAZINE. 
(a) INITIAL REPORT.—Not later than 18 months 
after the date of the enactment of this Act, the Attorney 
General, acting through the Administrator of the Drug 
Enforcement Administration and in coordination with the 
Commissioner of Food and Drugs, shall submit to Con-
gress a report on the prevalence of illicit use of xylazine 
VerDate Sep 11 2014 
22:27 Mar 10, 2025
Jkt 059200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H1266.IH
H1266
kjohnson on DSK7ZCZBW3PROD with $$_JOB
in the United States and the impacts of such use, includ-
ing— 
(1) where the drug is being diverted; 
(2) where the drug is originating; and 
(3) whether any analogues to xylazine, or re-
lated or derivative substances, exist and present a 
substantial risk of abuse. 
(b) ADDITIONAL REPORT.—Not later than 4 years 
after the date of the enactment of this Act, the Attorney 
General, acting through the Administrator of the Drug 
Enforcement Administration and in coordination with the 
Commissioner of Food and Drugs, shall submit to Con-
gress a report updating Congress on the prevalence and 
proliferation of xylazine trafficking and misuse in the 
United States. 
Æ 
VerDate Sep 11 2014 
22:27 Mar 10, 2025
Jkt 059200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6301
E:\BILLS\H1266.IH
H1266
kjohnson on DSK7ZCZBW3PROD with $$_JOB